As shown in Figure 5A, the relative expression of SRGN (p < 0.0001), FLI1 (p < 0.0001), and MACROH2A2 (p < 0.0001) in uEVs from patients with early-stage BC (n = 56) was significantly higher than those in uEVs from HC (n = 28). This evidence concerns the gene MACROH2A2 and breast cancer.